Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche

The bone marrow provides a protected environment for generating a vast array of cell types. Bones are thus a dynamic source of structural components and soluble factors used either locally or at a distance from their site of production. We discuss the role of ectoenzymes in the bone niche where human myeloma grows. Selected ectoenzymes have been tested for their ability to promote production of substrates involved in signaling, synthesis of growth factors and hormones, and modulation of the immune response. Because of the difficulty of simultaneously tracking all these activities, we narrow our focus to events potentially influencing synthesis of adenosine (ADO), an important regulator of multiple biological functions, including local immunological tolerance. Our working hypothesis, to be discussed and partially tested herein, is that CD38, and likely BST1/CD157—both NAD+‐consuming enzymes, are active in the myeloma niche and lead a discontinuous chain of ectoenzymes whose final products are exploited by the neoplastic plasma cell as part of its local survival strategy. Coadjuvant ectoenzymes include PC‐1/CD203a, CD39, and CD73, which control the production of ADO. Results discussed here and from ongoing experiments indicate that the myeloma niche hosts the canonical, as well as alternative, pathways of ADO generation. Other possibilities are presented and discussed.

[1]  S. Jalkanen,et al.  Metabolism of circulating ADP in the bloodstream is mediated via integrated actions of soluble adenylate kinase‐1 and NTPDase1/CD39 activities , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  D. Friedman,et al.  CD39 and control of cellular immune responses , 2007, Purinergic Signalling.

[3]  Eva C. Arnspang,et al.  Anti-Human CD73 Monoclonal Antibody Inhibits Metastasis Formation in Human Breast Cancer by Inducing Clustering and Internalization of CD73 Expressed on the Surface of Cancer Cells , 2013, The Journal of Immunology.

[4]  M. Kikuchi,et al.  CD38 gene knockout juvenile mice: a model of oxytocin signal defects in autism. , 2011, Biological & pharmaceutical bulletin.

[5]  N. Scrutton,et al.  Crystal Structure of a Soluble Form of Human CD73 with Ecto‐5′‐Nucleotidase Activity , 2012, Chembiochem : a European journal of chemical biology.

[6]  J. Schrader,et al.  Formation of S-adenosylhomocysteine in the heart. I: An index of free intracellular adenosine. , 1988, Circulation research.

[7]  Pál Pacher,et al.  Adenosine receptors: therapeutic aspects for inflammatory and immune diseases , 2006, Nature Reviews Drug Discovery.

[8]  L. Antonioli,et al.  Immunity, inflammation and cancer: a leading role for adenosine , 2013, Nature Reviews Cancer.

[9]  Purinergic signalling in endocrine organs , 2014, Purinergic Signalling.

[10]  S. Deaglio,et al.  CD38 and CD157 as Receptors of the Immune System: A Bridge Between Innate and Adaptive Immunity , 2006, Molecular medicine.

[11]  B. Cronstein,et al.  Adenosine and bone metabolism , 2013, Trends in Endocrinology & Metabolism.

[12]  J. Goding,et al.  Physiological and pathophysiological functions of the ecto-nucleotide pyrophosphatase/phosphodiesterase family. , 2003, Biochimica et biophysica acta.

[13]  Silvia Deaglio,et al.  CD38 and chronic lymphocytic leukemia: a decade later. , 2011, Blood.

[14]  D. Rossi,et al.  E2A is a transcriptional regulator of CD38 expression in chronic lymphocytic leukemia , 2011, Leukemia.

[15]  T. Whiteside,et al.  Adenosine production by human B cells and B cell-mediated suppression of activated T cells. , 2013, Blood.

[16]  T. Yoshino,et al.  Effect of adenosine receptor subtypes stimulation on mixed lymphocyte reaction. , 2007, European journal of pharmacology.

[17]  N. Nassif,et al.  Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma , 2014, Leukemia & lymphoma.

[18]  J. Laubach,et al.  Daratumumab granted breakthrough drug status , 2014, Expert opinion on investigational drugs.

[19]  M. Ferracin,et al.  Anti-CD38 Antibody Therapy: Windows of Opportunity Yielded by the Functional Characteristics of the Target Molecule , 2013, Molecular Medicine.

[20]  J. Sévigny,et al.  The C-terminal cysteine-rich region dictates specific catalytic properties in chimeras of the ectonucleotidases NTPDase1 and NTPDase2. , 2001, European journal of biochemistry.

[21]  B. Fredholm,et al.  International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An Update , 2011, Pharmacological Reviews.

[22]  W. Junger,et al.  Immune cell regulation by autocrine purinergic signalling , 2011, Nature Reviews Immunology.

[23]  G. Storm,et al.  Human Regulatory T Cells Do Not Suppress the Antitumor Immunity in the Bone Marrow: A Role for Bone Marrow Stromal Cells in Neutralizing Regulatory T Cells , 2013, Clinical Cancer Research.

[24]  G. Mundy,et al.  Osteoclasts in Multiple Myeloma Are Derived from Gr-1+CD11b+Myeloid-Derived Suppressor Cells , 2012, PloS one.

[25]  A. Mackensen,et al.  A humanized mouse identifies the bone marrow as a niche with low therapeutic IgG activity. , 2014, Cell reports.

[26]  R. Ebstein,et al.  Are retinoids potential therapeutic agents in disorders of social cognition including autism? , 2011, FEBS letters.

[27]  J. Baldwin,et al.  Structure and function of receptors coupled to G proteins. , 1994, Current opinion in cell biology.

[28]  R. Graeff,et al.  ADP-ribosyl Cyclase and CD38 Catalyze the Synthesis of a Calcium-mobilizing Metabolite from NADP+(*) , 1995, The Journal of Biological Chemistry.

[29]  M. Chilosi,et al.  Human myeloma cells express the CD38 ligand CD31 , 1999, British journal of haematology.

[30]  R. Senetta,et al.  Contribution of adenosine-producing ectoenzymes to the mechanisms underlying the mitigation of maternal-fetal conflicts. , 2013, Journal of biological regulators and homeostatic agents.

[31]  S. Toyosawa,et al.  CD73‐generated adenosine promotes osteoblast differentiation , 2012, Journal of cellular physiology.

[32]  O. Garson,et al.  Plasma cell membrane glycoprotein PC-1. cDNA cloning of the human molecule, amino acid sequence, and chromosomal location. , 1990, The Journal of biological chemistry.

[33]  Makoto Sato,et al.  Anxiety- and depression-like behavior in mice lacking the CD157/BST1 gene, a risk factor for Parkinson's disease , 2014, Front. Behav. Neurosci..

[34]  Ying Zhao,et al.  E proteins regulate osteoclast maturation and survival , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[35]  S. Deaglio,et al.  Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. , 2008, Physiological reviews.

[36]  M. Pastor-Anglada,et al.  Concentrative nucleoside transporters (CNTs) in epithelia: from absorption to cell signaling , 2007, Journal of Physiology and Biochemistry.

[37]  S. Colgan,et al.  Central role of Sp1-regulated CD39 in hypoxia/ischemia protection. , 2009, Blood.

[38]  M. Doucet,et al.  Enpp1: A Potential Facilitator of Breast Cancer Bone Metastasis , 2013, PloS one.

[39]  Linheng Li,et al.  The stem cell niches in bone. , 2006, The Journal of clinical investigation.

[40]  J. Klawitter,et al.  Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice. , 2017, The Journal of clinical investigation.

[41]  T. Yuen,et al.  Regulated production of the pituitary hormone oxytocin from murine and human osteoblasts. , 2011, Biochemical and biophysical research communications.

[42]  S. Colgan,et al.  Crucial Role for Ecto-5′-Nucleotidase (CD73) in Vascular Leakage during Hypoxia , 2004, The Journal of experimental medicine.

[43]  M. Howard,et al.  Ecto‐enzymes of lymphoid cells , 1998, Immunological reviews.

[44]  J. Goding Ecto‐enzymes: physiology meets pathology , 2000, Journal of leukocyte biology.

[45]  L. Rybak,et al.  Adenosine Receptors: Expression, Function and Regulation , 2014, International journal of molecular sciences.

[46]  T. Yuen,et al.  Bone Marrow Oxytocin Mediates the Anabolic Action of Estrogen on the Skeleton* , 2012, The Journal of Biological Chemistry.

[47]  V. Kuchroo,et al.  IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39 , 2013, Nature Immunology.

[48]  Bin Zhang CD73 promotes tumor growth and metastasis , 2012, Oncoimmunology.

[49]  D. Wiest,et al.  The TCR ligand-inducible expression of CD73 marks γδ lineage commitment and a metastable intermediate in effector specification , 2014, The Journal of experimental medicine.

[50]  M. Sitkovsky,et al.  Purinergic signaling during inflammation. , 2012, The New England journal of medicine.

[51]  Laurens P. Kil,et al.  Targeting Bruton's tyrosine kinase in B cell malignancies , 2014, Nature Reviews Cancer.

[52]  F. Malavasi,et al.  CD38 and bone marrow microenvironment. , 2014, Frontiers in bioscience.

[53]  F. Malavasi,et al.  Exosomes from human lymphoblastoid B cells express enzymatically active CD38 that is associated with signaling complexes containing CD81, Hsc-70 and Lyn. , 2010, Experimental cell research.

[54]  N. Hatch,et al.  Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) Protein Regulates Osteoblast Differentiation , 2011, The Journal of Biological Chemistry.

[55]  T. Gudermann,et al.  The structural basis of G-protein-coupled receptor function and dysfunction in human diseases. , 2002, Reviews of physiology, biochemistry and pharmacology.

[56]  H. Nishimasu,et al.  Crystal structure of Enpp1, an extracellular glycoprotein involved in bone mineralization and insulin signaling , 2012, Proceedings of the National Academy of Sciences.

[57]  F. Malavasi,et al.  A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes , 2013, Oncoimmunology.

[58]  J. Eliaou,et al.  ENTPD1/CD39 is a promising therapeutic target in oncology , 2013, Oncogene.

[59]  L. Old,et al.  SURFACE ALLOANTIGENS OF PLASMA CELLS , 1970, The Journal of experimental medicine.

[60]  R. Parkhouse,et al.  Location of nucleotide pyrophosphatase and alkaline phosphodiesterase activities on the lymphocyte surface membrane. , 1976, The Biochemical journal.

[61]  N. Munshi,et al.  Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. , 2013, Blood.

[62]  J. Stagg The double-edge sword effect of anti-CD73 cancer therapy , 2012, Oncoimmunology.

[63]  T. Seike,et al.  CD38 is critical for social behaviour by regulating oxytocin secretion , 2007, Nature.

[64]  T. Yuen,et al.  The Oxytocin–Bone Axis , 2014, Journal of neuroendocrinology.

[65]  E. Vizi,et al.  CD39 and CD73 in immunity and inflammation. , 2013, Trends in molecular medicine.

[66]  F. Malavasi,et al.  CD38 and CD157: A long journey from activation markers to multifunctional molecules , 2013, Cytometry. Part B, Clinical cytometry.

[67]  A. Uccelli,et al.  Mesenchymal stem cells in health and disease , 2008, Nature Reviews Immunology.

[68]  B. Ryffel,et al.  Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression. , 2012, Immunity.